Literature DB >> 11719352

Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase.

J D Phillips1, T L Parker, H L Schubert, F G Whitby, C P Hill, J P Kushner.   

Abstract

Functional consequences of 12 mutations-10 missense, 1 splicing defect, and 1 frameshift mutation-were characterized in the uroporphyrinogen decarboxylase (URO-D) gene found in Utah pedigrees with familial porphyria cutanea tarda (F-PCT). All but one mutation altered a restriction site in the URO-D gene, permitting identification of affected relatives using a combination of polymerase chain reaction and restriction enzyme digestion. In a bacterial expression system, 3 of the missense mutants were found in inclusion bodies, but 7 were expressed as soluble proteins. Enzymatic activity of soluble, recombinant mutant URO-D genes ranged from 29% to 94% of normal. URO-D mRNA levels in Epstein-Barr-virus transformed cells derived from patients were normal (with the exception of the frameshift mutation) even though protein levels were lower than normal, suggesting that missense mutations generally cause unstable URO-Ds in vivo. The crystal structures of 3 mutant URO-Ds were solved, and the structural consequences of the mutations were defined. All missense mutations reported here and by others were mapped to the crystal structure of URO-D, and structural effects were predicted. These studies define structural and functional consequences of URO-D mutations occurring in patients with F-PCT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719352     DOI: 10.1182/blood.v98.12.3179

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

Review 2.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

3.  Hepatoerythropoietic porphyria due to a novel mutation in the uroporphyrinogen decarboxylase gene.

Authors:  J To-Figueras; J D Phillips; J M Gonzalez-López; C Badenas; I Madrigal; E M González-Romarís; C Ramos; J M Aguirre; C Herrero
Journal:  Br J Dermatol       Date:  2011-08-18       Impact factor: 9.302

4.  Structural and kinetic characterization of mutant human uroporphyrinogen decarboxylases.

Authors:  C A Warby; J D Phillips; H A Bergonia; F G Whitby; C P Hill; J P Kushner
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-07-01       Impact factor: 1.770

5.  Substrate shuttling between active sites of uroporphyrinogen decarboxylase is not required to generate coproporphyrinogen.

Authors:  John D Phillips; Christy A Warby; Frank G Whitby; James P Kushner; Christopher P Hill
Journal:  J Mol Biol       Date:  2009-04-10       Impact factor: 5.469

6.  Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives.

Authors:  C Badenas; J To-Figueras; J D Phillips; C A Warby; C Muñoz; C Herrero
Journal:  Clin Genet       Date:  2009-04       Impact factor: 4.438

7.  Abnormal concentration of porphyrins in serum from COVID-19 patients.

Authors:  Itxaso San Juan; Chiara Bruzzone; Maider Bizkarguenaga; Ganeko Bernardo-Seisdedos; Ana Laín; Rubén Gil-Redondo; Tammo Diercks; Jon Gil-Martínez; Pedro Urquiza; Eunate Arana; Marisa Seco; Aitor García de Vicuña; Nieves Embade; José M Mato; Oscar Millet
Journal:  Br J Haematol       Date:  2020-08-29       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.